News | August 20, 2009

McKesson's Molecular Diagnostics Criteria Surpasses 380 Tests

August 20, 2009 - McKesson updated its InterQual Molecular Diagnostics Criteria to cover more than 380 tests, including a new category of pharmacogenomic tests that determine if an individual will be responsive to a drug based on genetic makeup.

As the first vendor to provide a comprehensive set of evidence-based criteria to support decision-making for molecular diagnostic tests, McKesson is now extending the power of this offering to help healthcare payors and providers to ensure patients receive the most appropriate medical care and better manage medical spend.
The added content in InterQual Molecular Diagnostics Criteria nearly doubles the number of tests included and addresses approximately 85-90 percent of the costs in this growing area. Criteria for over 70 pharmacogenomic tests are now available, including BCR-ABL1 (Philly Chromosome) and C-Kit for response to tyrosine kinase inhibitors used to treat certain types of leukemia, and KRAS for response to tyrosine kinase inhibitors for non-small cell lung cancer and advanced pancreatic cancer.
Pharmacogenomic tests, which can predict individual patient response to many specialty pharmaceuticals, help patients get needed, effective care faster. Although they may cost anywhere from a few hundred dollars to over $1,000, these tests have the potential to save as much as $100,000 per year in unnecessary pharmaceutical spending.
Growing at a staggering rate, molecular and genetic test volumes have reached 40 million annual tests in the United States and are expected to double to 80 million by 2012 according to Washington G-2 Reports (2008).Though this fast-growing field holds great promise, it also presents challenges for both health plans and providers as they try to determine test appropriateness and stay educated about medical necessity and test efficacy.

For more information: www.mckesson.com

Related Content

National Clinical Decision Support Company (NDSC) has an exclusive deal with the American College of Radiology (ACR) to provide medical imaging appropriate use criteria (AUC).

National Clinical Decision Support Company (NDSC) has an exclusive deal with the American College of Radiology (ACR) to provide medical imaging appropriate use criteria (AUC). 

Feature | Clinical Decision Support | January 18, 2018
January 18, 2018 — Change Healthcare announced the acquisition of National Decision Support Company (NDSC), a leader
News | Clinical Decision Support | January 12, 2018
January 12, 2018 — GE Healthcare has entered into a strategic, long-term partnership with Roche to jointly develop an
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Mirada Medical and Optellum Debut AI-Based Lung Cancer Diagnosis Solution at RSNA 2017
News | Computed Tomography (CT) | December 14, 2017
Optellum, a high-tech startup in lung cancer and machine learning, and Mirada Medical recently announced a partnership...
HealthMyne Highlights Value of Quantitative Data in Oncology Reads at RSNA 2017
News | Clinical Decision Support | November 17, 2017
November 17, 2017 — At the 2017 Radiological Society of North America (RSNA) conference, HealthMyne will demonstrate
Intelerad Announces Partnership With MedCurrent
News | Clinical Decision Support | November 13, 2017
November 13, 2017 — Intelerad Medical Systems announced a partnership that will see MedCurrent’s OrderWise...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
HealthMyne QIDS 3.0 Platform Addresses Incidental Findings Workflow
Technology | PACS Accessories | October 18, 2017
October 18, 2017 — HealthMyne announced the release of QIDS (Quantitative Imaging Decision Support) 3.0 with the Inci
Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support | October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
ACR Appropriateness Criteria Add Topics, Increase Diagnostic Imaging Clinical Scenarios
News | Clinical Decision Support | October 11, 2017
October 11, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the...
Overlay Init